These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 10561024)

  • 1. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
    Treon SP; Raje N; Anderson KC
    Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP; Anderson KC
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.
    Treon SP; Shima Y; Grossbard ML; Preffer FI; Belch AR; Pilarski LM; Anderson KC
    Ann Oncol; 2000; 11 Suppl 1():107-11. PubMed ID: 10707790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
    Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
    Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother (1991); 2001 May; 24(3):263-271. PubMed ID: 11395643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and phase I and II trials of rituximab.
    Maloney DG
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
    Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
    J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: an insider's historical perspective.
    Grillo-López AJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
    Treon SP; Pilarski LM; Belch AR; Kelliher A; Preffer FI; Shima Y; Mitsiades CS; Mitsiades NS; Szczepek AJ; Ellman L; Harmon D; Grossbard ML; Anderson KC
    J Immunother; 2002; 25(1):72-81. PubMed ID: 11924912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in indolent lymphoma: the single-agent pivotal trial.
    McLaughlin P; Hagemeister FB; Grillo-López AJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
    Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
    Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.